A director at Sanofi bought 500 shares at 82.700EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
La directive européenne NIS2 (sur la cybersécurité), en cours d’implémentation, va être un soutien pour le segment commercial en Europe d’Assa Abloy. Ceci associé à une reprise dans les pays nordiques en résidentiel et un segment commercial US toujours solide devraient aider progressivement à retrouver une meilleure dynamique de la topline (retour vers les 4-5%) et compenser le sentiment négatif associé aux perspectives décevantes du résidentiel US. Opinion Surperformance confirmée, OC relevé à ...
The European NIS2 directive (on cyber security), currently being implemented, should provide support for Assa Abloy's commercial segment in Europe. This, combined with a recovery in the residential segment in Nordic countries and a still solid US commercial segment, should gradually help to improve top line momentum (return towards 4-5%) and offset the negative sentiment associated with the disappointing outlook for the US residential market. Outperform rating confirmed – target price raised to ...
ArcelorMittal publishes its 2024 Payments to governments in respect of extractive activities report 30 June 2025, 16:00 CET ArcelorMittal (’the Company’) has today filed its 2024 Payments to governments in respect of extractive activities report, which provides a consolidated overview of payments made by the Company and its subsidiaries in 2024 to governments regarding its mining operations. The report, which complies with reporting requirements under Luxembourg law, is available for download from . ENDS About ArcelorMittal ArcelorMittal is one of the world’s leading integrated steel a...
Press release: Availability of the Q2 2025 Aide mémoire Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be published on July 31, 2025. About Sanofi...
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire » Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du premier tri...
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatmentJapanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address significant unmet medical needs for people living...
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les personnes atteintes de PIDC comme traitement potentiel meilleur de sa catégorieLa décision du ministère de la Santé, du Travail et des Affaires sociales du Japon s’ajoute aux désignations similaires aux États-Unis et en ...
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipientsRiliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.